Mr. Andre Larente reports

DIAGNOS ANNOUNCES AMENDMENT TO CONVERTIBLE DEBENTURES

Diagnos Inc. intends to amend the terms of an aggregate amount of $590,000 of unsecured convertible debentures issued as part of a private placement of units initially announced on March 1, 2022, as follows:

• The maturity date, initially set for March 1, 2025, is extended to March 1, 2026.
• The yearly interest rate is increased from 8 per cent to 10 per cent for the extended period from March 1, 2025, to March 1, 2026.

All other provisions of the debentures will remain unchanged and fully in effect during the extension period.

The amendment remains subject to the TSX Venture Exchange acceptance as well as execution of formal documentation.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation with a mission of developing software tools for the early detection of critical health issues through the use of artificial intelligence.

We seek Safe Harbor.